RT Journal Article
SR Electronic
T1 N-Palmitoyl glycine activates transient receptor potential channel 5 and increases the risk of Brugada syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.21.24315897
DO 10.1101/2024.10.21.24315897
A1 Xu, Hongxuan
A1 Li, Bingxun
A1 Chen, Ying
A1 Lin, Yanyun
A1 Zhang, An
A1 Wu, Lin
YR 2024
UL http://medrxiv.org/content/early/2024/10/22/2024.10.21.24315897.abstract
AB Background Brugada syndrome (BrS) is an arrhythmic disorder associated with an increased risk of sudden cardiac death; however, current treatment options are limited due to their side effects and variable efficacy.Methods In this study, we first employed Mendelian randomization analysis utilizing proteomic, transcriptomic, and metabolomic data to identify potential therapeutic targets for BrS. Ex vivo perfused heart models were used to assess the effects of the potential targets on action potentials and QT intervals. Calcium indicators were employed to evaluate calcium homeostasis in primary cardiomyocytes, and patch-clamp techniques were used to investigate the impact on Nav1.5 and TRPC5 channels.Results Our findings indicate that N-palmitoyl glycine (PalGly) is linked to an increased risk of BrS and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA. Electrophysiological experiments showed that although PalGly does not interact with Nav1.5, it enhances calcium sparks in ventricular cardiomyocytes. We determined that the calcium-modulating effect of PalGly is mediated by its binding to and activation of the transient receptor potential channel 5 (TRPC5) channel. Furthermore, PalGly was found to shorten the QT interval and action potential duration in Langendorff-perfused rabbit hearts and isolated rabbit cardiomyocytes. Transcriptomic and lipidomic analyses of PalGly-treated neonatal rat cardiomyocytes revealed significant negative modulation of immune pathways, akin to the effects observed with agonizing TRPC5.Conclusion Our study underscores the involvement of PalGly, TRPC5, and inflammation-related proteins in the pathophysiology of BrS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Chinese National Natural Science Foundation (Grant No. 81930105 and 82370312).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UKB participants gave informed written consent, and ethical approval was obtained from the North West Centre for Research Ethics Committee. The deCode participants who donated samples gave informed consent, and the National Bioethics Committee of Iceland approved the study. The All GWAS human participants provided written informed consent, and all studies had received approval from the appropriate ethical review boards. The animal ethical clearance was granted by the Institutional Animal Care and Use Committee of Peking University First Hospital (approved number: J2024090), affirming the conscientiousness of their treatment and welfare.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBrSBrugada syndromeICDimplantable cardioverter-defibrillatorMRmendelian randomizationECGelectrocardiogramGWASgenome-wide association studiesQTLquantitative trait lociPBMCperipheral blood mononuclear cellIVWInverse variance weightedApoA1apolipoprotein A1ApoBapolipoprotein BHDL-Chigh-density lipoprotein cholesterolLDL-Clow-density lipoprotein cholesterolLp(a)Lipoprotein ASBPsystolic blood pressureDBPdiastolic blood pressureHbA1cHemoglobin A1CBMIbody mass indexAFatrial fibrillationCHDcoronary heart diseaseHFheart failurePalGlyN-palmitoylglycineAPDaction potential durationFDG-PETfluorodeoxyglucose–positron-emission tomographyNONitric oxideDRGdorsal root ganglionDADdelayed afterdepolarizationsSCAsudden cardiac arrest